WILMINGTON, N.C.----PPD, Inc. today announced it has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome and the other to treat complicated skin and skin structure and respiratory infections.View the full article